Table-1.
Effects of resveratrol on various human cancer cells.
| TUMOR MODELS | CELL LINES USED | MOLECULAR TARGETS | CELLULAR EFFECT(S) | REFERENCES |
|---|---|---|---|---|
| Breast cancer | T47D MDA-MB-231 MDA-MB-468 MCF-7 |
p53, PTEN, p27, ROS, NO, QR, p21 | Apoptosis | (Alkhalaf, 2007; Kim et al., 2004; Kotha et al., 2006; Lanzilli et al., 2006; Lee and Safe, 2001; Pozo-Guisado et al., 2002; Pozo-Guisado et al., 2005; Waite et al., 2005) |
| p70S6K, ppS6RP, Src-Stat3, pAkt, Bcl-2, NF-κB, calpain, MMP-9, cyclin D, Cdk4, ribonucleotide reductase, CYP1A1, telomerase | Growth arrest Cell migration | |||
| Prostate cancer | LNCap PC-3 DU145 Colo-357 LAPC-4 |
Caspases 3/9, p53, p21, p27, Bax, Bak, Bid, Bad, MKP5 | Apoptosis, G0/G1-arrest | (Awad et al., 2005; Aziz et al., 2006; Benitez et al., 2007a; Kotha et al., 2006; Nonn et al., 2007) |
| PI3K, pAKT, cyclins B/D1/E, Cdk1/4, Bcl-2, Src-Stat3, ROS | Proliferation rate, cell viability | |||
| Colon cancer | HT-29 DLD1 HCT116 |
AMPK, ROS, cathepsin D, caspase-2, cytochrome c, ATF3 | Apoptosis, lysosome leakage, G2-arrest | (Bottone et al., 2005; Hwang et al., 2007; Liang et al., 2003; Mohan et al., 2006; Trincheri et al., 2007) |
| Cdk7, p34Cdc2 | Cell growth | |||
| Pancreatic cancer | CD18 S2-013 panc-1 |
MIC-1, cytochrome C, caspase-3 | apoptosis | (Golkar et al., 2007; Kotha et al., 2006; Mouria et al., 2002) |
| Src-Stat3, NF-κB | Cell growth | |||
| Leukemia | HL-60 | Apoptosis, nuclear size, granularity | (Quiney et al., 2004; Stervbo et al., 2006) | |
| NO | Cell growth | |||
| Hepatoma | HepG2 | Apoptosis, nuclear size, granularity | (Stervbo et al., 2006) | |
| Cell growth | ||||
| B-cell Lymphoma | LY1 LY8 LY18 |
p27, p53, CD69 | Apoptosis, G0/G1-arrest | (Faber and Chiles, 2006; Faber et al., 2006) |
| BCL6, Myc, pAKT, pp70S6K | glycolysis | |||
| Osteosarcoma | SJSA1 | pERK1/2, pp53(Ser15) | Apoptosis | (Alkhalaf and Jaffal, 2006) |
| Cell growth | ||||
| Squamous cell carcinoma | A431 | p21, p27 | G0/G1-arrest | (Adhami et al., 2001; Ahmad et al., 2001; Kim et al., 2006; Zhang et al., 2005) |
| Cyclins A/E/D1/D2 Cdk2/4/6, pRb, MEK1, pERK1/2, c-Jun, AP-1, HIF-1α, VEGF, Akt, E2F1-5, DP1/2 | ||||
| Multiple Myeloma | RPMI8226 OPM-2 U266 KM3 |
c-fms, CD14, CD11a, 1,25(OH)2D3 nuclear receptor, Bax, Apaf-1 | apoptosis | (Boissy et al., 2005; Jazirehi and Bonavida, 2004; Sun et al., 2006b) |
| Cathepsin K, RANK, NFATc1, NF-κB nuclear translocation, Bcl-2, Bcl-x(L), XIAP, Mcl-1, MMP-2, MMP-9 | ||||
| Rhabdomyosarcoma | S/G2-arrest | (Chow et al., 2005) | ||
| Cyclin B | ||||
| Ovarian Carcinoma | Ovcar-3 A2780/CP70 CaOV3 ES-2 TOV112D A1947 |
pCdc2(tyr15), ATM/ATR, chk1/2, pCdc25C, pH2A.X(ser139), | S-arrest, autophagocytic death | (Cao et al., 2004; Opipari et al., 2004; Tyagi et al., 2005) |
| Akt, HIF-1α, VEGF | ||||
| Medulloblastoma | UW228-2 UW228-3 |
CYP1A1 | Apoptosis, differentiation | (Liu et al., 2004; Zhang et al., 2006) |
| CYP1B1,c-Myc | ||||
| Acute myeloid leukemia | OCIM2 OCI/AML3 |
S-arrest, apoptosis | (Estrov et al., 2003) | |
| IL-1β, NF-κB | ||||
| Thyroid cancer | PTC FTC |
P53, p53(ser15), c-fos, c-jun, p21 | apoptosis | (Shih et al., 2002) |
| Gastric adenocarcinomas | KATO-III RF-1 |
G0/G1-arrest, apoptosis | (Atten et al., 2001) | |
| PKC, PKCα | DNA synthesis |
Upregulation and increased activities of molecular targets are represented in the upper rows, and inhibition and decreased activities in the bottom rows for each tumor model.